Gujarat Themis Biosyn Ltd. (BSE: 506879) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹5,051 Cr, it ranks #832 by market cap among the 6,197 Indian listed companies on FinBizNet, and #26 of 86 in Medicinal Chemicals and Botanical Products. At ₹389.00 (as of 16 Nov 2026), the share price is 17.2% below its 52-week high of ₹470.05 and 72.9% above its 52-week low of ₹225.05. The share price is down 13.7% over one year and up 11.9% over three months.
| Current Price | ₹389.00 |
|---|---|
| Market Cap | ₹5,051 Cr |
| BSE Code | 506879 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 90.8 |
| Return on Equity | 17.41% |
| Return on Assets | 9.74% |
| 52-Week Range | ₹225.05 – ₹470.05 |
| 1-Year Price Change | -13.7% |
| 3-Month Price Change | +11.9% |
| Beta (1Y) | 0.71 |
| Dividend Yield | 0.17% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.gtbl.in |
| Revenue | ₹50 Cr |
|---|---|
| Net Profit | ₹-14 Cr |
| Net Margin | -27.7% |
| EPS (Basic) | ₹-1.19 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Promoters held 59.33% of Gujarat Themis Biosyn Ltd.'s shares as of Sept 2026, against 70.86% in Dec 2025 (−11.53 percentage points). Delivery averaged 50.5% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Gujarat Themis Biosyn Limited engages in the manufacture of pharmaceuticals and medicinal chemicals in India. The company offers bulk drugs on job work basis in India. Its products include Rifamycin-S, an intermediate for the treatment of tuberculosis, Mycobacterium avium complex, leprosy, and Legionnaires' disease; Rifamycin-O for the treatment of traveler's diarrhea, irritable bowel syndrome, and hepatic encephalopathy; and Lovastatin. The company was incorporated in 1981 and is based in Mumbai, India.
1. Manufacturing Bulk Drugs-This segment manufactures bulk drugs.
1. Manufacturing Bulk Drugs-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,56,425 Cr | 39.5 | 14.72% | ₹16,199 Cr | +11.2% |
| Laurus Labs Ltd | ₹1,31,242 Cr | 145.6 | 17.74% | ₹2,206 Cr | +146.8% |
| Zydus Lifesciences Ltd | ₹1,19,651 Cr | 24.1 | 18.32% | ₹7,910 Cr | +26.0% |
| Dr.Reddys Lab | ₹1,15,464 Cr | 26.9 | 11.52% | ₹8,698 Cr | +14.5% |
| Cipla Limited | ₹1,14,712 Cr | 29.3 | 11.74% | ₹7,404 Cr | -7.6% |
| Mankind Pharma | ₹1,09,870 Cr | 57 | 12.45% | ₹4,338 Cr | +16.7% |
| Aurobindo Pharma Ltd. | ₹1,05,150 Cr | 30 | 9.93% | ₹10,263 Cr | +59.8% |
| Lupin Ltd | ₹92,087 Cr | 17.3 | 26.91% | ₹7,827 Cr | +0.4% |
| Gujarat Themis Biosyn Ltd. | ₹5,051 Cr | 90.8 | 17.41% | ₹50 Cr | -13.7% |
Listed by market capitalisation. Ratios are shown for context only.
Gujarat Themis Biosyn Ltd. is trading at ₹389.00, with a market capitalisation of ₹5,051 Cr.
Gujarat Themis Biosyn Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Gujarat Themis Biosyn Ltd. has a P/E of 90.8 and a return on equity of 17.41%.
Gujarat Themis Biosyn Ltd. is listed on the BSE under the scrip code 506879.
Gujarat Themis Biosyn Ltd.'s share price is down 13.7% over one year and up 11.9% over three months. Its 52-week range is ₹225.05 to ₹470.05.
In Q2 FY27, Gujarat Themis Biosyn Ltd. reported revenue of ₹50 Cr and net profit of ₹-14 Cr, with basic EPS of ₹-1.19 (consolidated, parsed from the company's exchange filing).
Promoters held 59.33% of Gujarat Themis Biosyn Ltd.'s shares as of Sept 2026, against 70.86% in Dec 2025 (−11.53 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.